Brain & Behavioral Health Institute and NIDA Southwest CTN Node Presents:
Targeting Solutions for Future Clinical Pain Management
September 23rd, 2021, 4:00-5:00pm
Novel scFv antibodies and patient samples are being characterized in pre-clinical studies designed to target potential chronic pain therapies. The scFvs are being validated with animal behavioral and a human stem cell platform. Using a combination of electrophysiological, molecular and cell biology approaches, samples (CSF and blood) from chronic pain patients have a primary focus on how this might influence nociceptor excitability. We hope that these studies will lead to the discovery of novel targets for treating specific chronic pain conditions.